TY - JOUR T1 - Leveraging Experience From Active TB Drug-Safety Monitoring and Management for Monitoring Active Antiretroviral Toxicity JF - Global Health: Science and Practice JO - GLOB HEALTH SCI PRACT DO - 10.9745/GHSP-D-21-00595 VL - 10 IS - 2 SP - e2100595 AU - Lisa Stevens AU - Kelly E. Perry AU - Iakuna Moide AU - Francil Kaemala AU - Justine Nankinga AU - Anh L. Innes AU - Ignatius Mogaba Y1 - 2022/04/28 UR - http://www.ghspjournal.org/content/10/2/e2100595.abstract N2 - Key MessagesThe introduction of novel medicines and regimens for antiretroviral (ARV) and TB treatment requires comprehensive surveillance systems for adverse events and adverse drug reactions.Many TB programs have introduced and institutionalized active drug safety monitoring and management (aDSM) platforms for drug-resistant TB.Because HIV programs must develop active ARV toxicity monitoring systems to ensure safe global scale-up of newer regimens, such as tenofovir-lamivudine-dolutegravir, we propose building on existing aDSM infrastructure to actively monitor ARV regimens as a synergistic TB/HIV collaborative activity and to narrow active toxicity monitoring gaps.TB and HIV are preventable diseases, yet both continue to cause significant suffering and loss of life worldwide. Although concerted efforts have led to declining TB and HIV incidence and mortality, much remains to be done to reach global goals.1,2 Countries strive to reach “95-95-95” goals established by the Joint United Nations Programme on HIV/AIDS (UNAIDS), which include 95% of people living with HIV (PLHIV) knowing their status, 95% of those known to have HIV taking antiretroviral therapy (ART), and 95% of PLHIV on ART achieving viral suppression.3 Global TB programs endeavor to achieve the END TB Strategy goals set by the World Health Organization (WHO), including 95% global reduction in deaths due to TB and 90% reduction in TB incidence by 2035 compared to 2015.4Although declining incidence is multifactorial and strategies differ between TB and HIV programming, one critical contributor to reduced incidence and mortality has been the development of new medicines and better treatment regimen options, especially for HIV and multidrug-resistant (MDR) TB.For many years after initial ART introduction in resource-limited settings, programs relied on regimens containing either zidovudine or stavudine. Zidovudine is known to cause myelosuppression, with a study in northeastern Nigeria showing that anemia developed in 22.3% of those taking the … ER -